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Abstract 
Understanding how MAIT cells respond to infection has been hampered by the absence of reagents to 
detect these cells. Using MR1 tetramers, the functionality and phenotype of MAIT cells were 
determined in a mouse model of bacterial lung infection. MAIT cells were rapidly enriched in the 
lungs of C57BL/6 mice infected with Salmonella Typhimurium, comprising approximately half of all 
ab T-cells after one week. MAIT cell accumulation in the lungs was MR1-dependent and required an 
intact microbial riboflavin synthesis pathway. This accumulation did not occur in response to 
synthetic antigen, unless accompanied by a TLR2/6 agonist or by co-infection with riboflavin 
pathway-deficient Salmonella, involved proliferation in the lungs and regional LN, and was 
associated with their long-term retention in the lungs. Lung MAIT cells from infected mice were 
mainly DN or CD8+, displayed an activated/memory phenotype and most expressed the transcription 
factor RORgt with a small subset expressing T-bet. The majority of these cells produced IL-17, while 
a smaller subset produced	 IFNg detected directly ex vivo. Thus, the activation and expansion of 
MAIT cells, coupled with their pro-inflammatory cytokine production, occur in response to antigens 
derived from microbial riboflavin synthesis and are augmented by co-stimulatory signals. 
 
INTRODUCTION 
Mucosal-associated Invariant T (MAIT) cells are emerging as an important class of T cell that bridge 
innate and adaptive cellular immunity. The function of MAIT cells in immunity is still being 
elucidated, but an important role is suggested by their conservation across mammalian species. MAIT 
cells recognize conserved microbial metabolites generated by the riboflavin synthesis pathway and 
captured by the monomorphic MHC class 1–related protein (MR1) (Birkinshaw, 2014; Corbett et al., 
2014; Kjer-Nielsen et al., 2012).  MAIT cells express a conserved abTCR, which uses a common 
TCRa-chain coupled with a restricted set of TCR b-chains that are relatively conserved in both 
humans and mice (Gapin, 2009; Le Bourhis et al., 2011; Treiner et al., 2003). In mice, the MAIT 
TCR uses TRAV1-TRAJ33 (Va19-Jα33) generally assembled with the TCRb-chains TRBV19 (Vb6) 
or TRBV13 (Vb8). In humans most MAIT cells express TRAV1-2-TRAJ33 (Va7.2-Ja33), but with 
a significant proportion expressing TRAV1-2-TRAJ12 or TRAV1-2-TRAJ20 gene combinations	
(Reantragoon et al., 2013). These TCRa-chains form receptors with TRBV20 (Vb2) or TRBV6 
(Vb13) b-chains (Tilloy et al., 1999). 
 
Mention transcription factors, PLZF, RORgT, other markers, CD161, IL-18r, CD26 in humans. To 
date, characterisation of MAIT cell behaviour and phenotype in models of infectious diseases has 
largely depended on analysis of the DN T cell population and the use of PCR to detect the Va19 
expressed by MAIT cells or by the use of Va19 transgenic mice	 (Chiba et al., 2012; Gold et al., 
2010; Le Bourhis et al., 2011; Le Bourhis et al., 2010; Meierovics et al., 2013; Miyazaki et al., 2011). 
While this TCR Va-region is characteristic of MAIT cells, it is also expressed by many non-MAIT 
cells, including CD1-restricted GEM T cells and other conventional ab-T cells (Van Rhijn et al., 
2013; van Schaik et al., 2014, Tynan et al, NI, Rossjohn ARI 2015). In addition, inbred mice have 
very low numbers of blood and lymphoid MAIT cells compared with humans (Tilloy et al., 1999), 
and while transgenic models of MAIT cells have been used to help circumvent some of these 
problems (Kawachi et al., 2006; Martin et al., 2009), these mice force expression of Va19-bearing 
TCRs, and the relationship between these cells and MAIT cells is unclear. 
 
We recently identified products of the microbial riboflavin synthesis pathway as a major source of 
physiological antigen driving MAIT cell activation in vitro (Corbett et al., 2014; Kjer-Nielsen et al., 
2012; Patel et al., 2013). It is unclear whether this pathway is the exclusive source of activating 
antigen in vivo, as Vb chain and CDR3b diversity in MAIT TCRs and differential responses to 
diverse pathogens might reflect diversity or relative abundance in natural activating MAIT ligands 
(Eckle et al., 2014; Gold et al., 2014).Meermeier, Submitted Indeed, a number of MAIT cell antigens 
have been identified, including 5-(2-oxoepropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), 5-
(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU), 6,7-dimethyl-8-D-ribityllumazine (RL-
6,7-diMe) and 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH), some of which vary 
considerably in potency, as well as non-stimulatory MR1 ligands including 6-formyl-pterin (6-FP), a 
natural breakdown product of folic acid (Corbett et al., 2014; Kjer-Nielsen et al., 2012). 5-OP-RU 
and 5-OE-RU, the most potent MAIT cell antigens, are created from the riboflavin precursor 5-
amino-6-D ribitylaminouracil (5-A-RU) by non-enzymatic condensation with small ubiquitous 
metabolites methylglyoxal and glyoxal, respectively. The subsequent 5-OP-RU and 5-OE-RU 
products, though quite unstable pyrimidine adducts, are quickly captured by the Ag-presenting 
molecule MR1 and efficiently activate MAIT cells in vitro (Corbett et al., 2014). This finding has 
enabled the production of highly specific MR1-tetramers loaded with key natural MAIT antigens, 5-
OP-RU and 5-OE-RU (Corbett et al., 2014). Here we have examined the behaviour, functionality and 
phenotype of authentic MAIT cells, detected using specific MR1-Ag tetramers, in a bacterial lung 
infection model in wild-type C57BL/6 mice. Our data reveal that MAIT cell activation and 
accumulation in vivo was dependent on the presence of a functional riboflavin synthesis pathway in 
the microbial pathogen and required expression of MR1 in the host mice. Moreover, the phenotype 
and functional properties of responding MAIT cells suggest an important role for MAIT cells in 
infection and advance our understanding of their characteristics and functional capacity in vivo.  
 
RESULTS 
MAIT cells accumulate in the lungs of normal mice following infection with Salmonella 
Typhimurium 
We have previously used Salmonella enterocolitica, serovar Typhimurium (S. Typhimurium) to 
activate MAIT cells in vitro, and showed that the ability to stimulate these cells depends on the 
presence of an intact microbial riboflavin pathway, specifically involving genes necessary for the 
production of the riboflavin precursor compounds (Kjer-Nielsen et al., 2012) including 5-A-RU 
(Corbett et al., 2014). Our findings showed how 5-A-RU recombines with small metabolites to form 
MAIT-activating ligands, including the most potent MAIT-activating MR1 ligand identified to date, 
5-OP-RU (Corbett et al., 2014). Tetramers of MR1 loaded with 5-OP-RU specifically detect MAIT 
cells (Corbett et al., 2014; Reantragoon et al., 2013). MR1-5-OP-RU tetramers were used here to 
identify mouse MAIT cells (defined here as TCRb+MR1-tetramer+ cells) in single cell suspensions of 
lung, reproductive tract, liver, spleen, thymus, blood and mesenteric lymph nodes of naïve C57BL/6 
mice. MAIT cells represented ~2% of all ab-T cells in the reproductive tract, and up to 0.5-2% in 
lung, but there were generally lower proportions in blood and other organs (Fig 1a,b). In contrast, we 
could not detect MAIT cells in these organs from C57BL/6 MR1-/- mice (Fig 1a), confirming earlier 
findings that MR1 is vital for MAIT cell development (Martin et al., 2009). 
 
We next examined the impact of lung infection on MAIT cells in a model involving inoculation of 
mice with vaccine strain S. Typhimurium BRD509 (Strugnell et al., 1992). While S. Typhimurium is 
not a natural pathogen in the lung, it is known to activate MAIT cells in vitro and genetic 
manipulation of this bacterium now allows us to probe the Ag requirements for MAIT cell activation 
in vivo. Following intranasal infection with S. Typhimurium BRD509, there was a substantial 
enrichment of MAIT cells in the lungs of C57BL/6 mice such that they comprised 25-50% of all 
infiltrating lung ab-T cells after just one week (Fig 1b, c). MAIT cell enrichment was not present in 
C57BL/6.MR1-/- mice (Fig 1b, c) and was blocked by pre-treatment with MR1-specific mAbs, 26.5 
or 8F2 (Huang et al., 2005, and Chua et al JI 2013) administered prior to infection (Fig 1c, and not 
shown). These findings underscore the MR1-dependence of the MAIT cell accumulation and 
enrichment in the Salmonella lung model. The accumulation of lung MAIT cells was dependent on 
the size of the bacterial inoculum (Fig 1d) and peaked at day 7 post infection (d7 p.i.), (Fig 1e). In 
several experiments this peak was a few days earlier than the peak in accumulating non-MAIT ab-T 
cells (d10 p.i.) (Fig 1e), consistent with the notion that MAIT cells bridge innate and adaptive 
responses.  
 
In vivo accumulation and enrichment of MAIT cells post-infection requires an intact bacterial 
riboflavin pathway  
To confirm the requirement for microbial riboflavin metabolites in driving the in vivo MAIT cell 
response, we constructed a mutant strain of BRD509 in which ribD and ribH genes, which are co-
located in the Salmonella genome, were deleted; BRD509DribDH. While deficiency of the ribH gene 
does not impact on bacterial activation of MAIT cells (Corbett et al., 2014) the ribD gene is essential 
for production of the 5-A-RU precursor to the potent MAIT antigens, 5-OP-RU and 5-OE-RU 
(Corbett et al., 2014). The mutant BRD509DribDH bacteria were first tested in vitro and found to be 
deficient in their ability to stimulate reporter cells expressing a MAIT TCR (Jurkat.MAIT) (Kjer-
Nielsen et al., 2012) in an MR1-dependent activation assay (Fig. 2a). By comparison, BRD509 
supernatant (wt) caused a strong up-regulation of CD69 on the Jurkat.MAIT reporter cells (Fig. 2a). 
Supernatant from the BRD509DribDH bacteria reconstituted with the ribD and ribH genes 
(BRD509DribDH+ribDH) also activated the Jurkat.MAIT cells to wild type levels (Fig. 2a), 
confirming previous in vitro results obtained with mutants of another Salmonella strain, SL1344 
(Corbett et al., 2014).  
 
As shown above, infection of mice with the S. Typhimurium BRD509 led to accumulation and 
enrichment of lung MAIT cells to a level where they represented up to 50% of all lung ab-T cells. 
However, infection with BRD509DribDH bacteria did not evoke MAIT cell enrichment or 
accumulation in the lungs of mice beyond the resident MAIT cell numbers in uninfected lungs (Fig 
2b, c). The lack of MAIT cell accumulation following infection with BRD509DribDH bacteria was 
unlikely the result of their slower growth since mice infected with a 10 fold higher dose of 
BRD509DribDH bacteria, which results in equivalent bacterial counts at 2 weeks, still accumulated 
non-MAIT ab T-cells (not shown and Fig 2b). Moreover, the non-responsiveness of MAIT cells to 
infection with BRD509DribDH Salmonella could be rescued if the bacteria were co-administered 
intranasally with synthetic MAIT antigen 5-OP-RU (Fig. 2b, c). In contrast, co-administration of the 
BRD509 strain and the MR1-ligand 6-FP (Kjer-Nielsen et al., 2012), which does not activate MAIT 
cells, did not cause MAIT cell accumulation in the lungs (Fig. 2c), confirming the specificity of the 
response. Of note, 5-OP-RU alone caused no MAIT accumulation at any dose or time point tested, 
when delivered either intravenously or intranasal, suggesting that Ag alone is insufficient to induce 
the MAIT cell accumulation (Fig. 2d, f and not shown). This could reflect a requirement for co-
stimulation provided by the BRD509DribDH bacteria or the quite unstable nature of free 5-OP-RU 
failing to produce sustained MAIT cell stimulation. To examine whether a co-stimulus could be 
furnished through TLRs, we inoculated mice with 5-OP-RU and TLR agonist dipalmitoyl-S-glyceryl 
cysteine (Pam2Cys). Pam2Cys is a synthetic mimic of the lipid component of TLR2 and TLR6 
ligand macrophage activating lipopeptide-2 (MALP-2) and has been shown to be an agonist for 
TLR2 (Jackson et al., 2004; Lau et al., 2006). Challenge with Pam2Cys by itself, or with the non-
activating MR1 ligand 6-FP, led to a lesser (2-3-fold) enrichment for MAIT cells in the lungs 
suggesting co-stimuli alone can exert some influence on MAIT cells (Fig. 2d). In addition, although 
intranasal challenge with purified antigen alone did not induce accumulation of lung MAIT cells, it 
did induce rapid up-regulation of CD69 as early as 2 h following inoculation (Fig. 2e). However, the 
intranasal co-administration of synthetic antigen 5-OP-RU and Pam2Cys led to a 15-25 fold 
enrichment of MAIT cells in the lung in the absence of any bacterial challenge (Fig. 2d, f). This 
response was sustained over time (not shown) and was partially blocked by administration of anti-
MR1 mAb, (Fig. 2e). Thus, the failure of intranasal 5-OP-RU alone to drive MAIT cell enrichment 
was not the result of the lability of the antigen, suggesting that MAIT cell accumulation and 
enrichment requires stronger signals than those needed for activation. Indeed, repeated (x6) intranasal 
administration of 5-OP-RU alone over a seven-day period was still an insufficient stimulus to induce 
MAIT cell accumulation, despite sustained Ag exposure (Fig. 2f). Taken together, the findings 
demonstrate that Rib-defective (and thus MAIT antigen deficient) bacteria and a TLR2/6 agonist are 
independently capable of providing a co-stimulus that helps drive MAIT accumulation and 
enrichment in response to 5-OP-RU antigen in vivo (Fig. 2c, d).  
 
Infection induces IL-17 production, T-bet expression and the long-lived retention of 
phenotypically effector/memory MAIT cells in situ  
Upon activation in vitro, MAIT cells are known to produce IFNg, TNF and IL-17 (Dusseaux et al., 
2011; Meierovics et al., 2013) refs). This pattern of cytokine expression was mirrored following 
intranasal inoculation with S. Typhimurium (Fig. 3a). Most striking was the production of IL-17, 
which was detected in up to 50% of lung MAIT cells ex vivo at day 7 without further stimulation (Fig. 
3a). More interestingly, MAIT cells still appeared ‘primed’ to rapidly secrete IL-17 at day 120 p.i. 
(bottom left panel Fig. 3a), suggesting that MAIT cells acquire rapid responsiveness as they 
differentiate into their memory phase. In contrast, a higher proportion of non-MAIT ab-T cells 
produced IFNγ and TNF 7 days after infection than observed for MAIT cells (Fig. 3a). 
 
The transcriptional factor promyelocytic leukemia zinc finger (PLZF) is a master regulator of innate-
like T cell development, including Natural Killer T cells and some γδ T cells (Doulatov et al., 2009). 
Human MAIT cells express PLZF (Martin et al., 2009), although it is unclear whether it is expressed 
in mouse MAIT cells. Notably, PLZF was expressed on nearly all lung MAIT cells before and after 
infection, along with the orphan nuclear receptor, RORγt, which plays a key role in differentiation of 
Th17 cells (Crome et al., 2009), and which has previously been shown to be expressed by human 
MAIT cells (Dusseaux et al., 2011) (Fig. 3b left panels). In addition, we examined the expression of 
the transcription factor T-bet (encoded by Tbx21), a key regulator of Th1 type immunity, including 
the expression of IFNγ (Szabo et al., 2000). T-bet is reported to suppress IL-17 expression and 
promote Th1 development, whereas loss of T-bet expression can induce commitment to Th2 and loss 
of IFNγ expression (Lazarevic et al., 2011; Mathur et al., 2006; Villarino et al., 2010). The 
expression of RORγt declined slightly in MAIT cells as T-bet expression levels increased from d7-
142 p.i. Interestingly, the majority of cells at late time points co-expressed the two transcription 
factors (Fig. 3b, right panels). The production of IL-17 by MAIT cells d7 p.i., either ex vivo or when 
stimulated with PMA, was observed in the presence of either T-bet or RORγt (or both) (Fig. 3c). In 
contrast, at the same time point, a much smaller proportion of MAIT cells produced IFNγ after PMA 
stimulation and most of these expressed T-bet with <40% expressing RORγt and generally lower 
amounts of IFNγ (Fig. 3c). This pattern was even more evident for IFNγ production by non-MAIT 
cells. 
 
Even before infection, CD44, a marker of memory T cells, was expressed by most MAIT cells. 
However, the proportion of MAIT cells expressing the activation marker CD25 increased from 40% 
pre-infection to 73% at d100 p.i. (Fig. 3d), consistent with an effector/memory phenotype previously 
described for human MAIT cells (Dusseaux et al., 2011). In contrast, a smaller proportion of non-
MAIT ab-T cells expressed these markers pre-and p.i. (Fig. 3d). CD62L is a hallmark (CD62Lhigh) 
of a naïve phenotype, and further distinguishes central memory (CD62L+) from effector memory 
(CD62L−) for conventional T cells. The regulation of CD62L plays a pivotal role in controlling the 
traffic of conventional T lymphocytes to and from peripheral lymph nodes. CD62L is shed from the 
cell membrane following activation of conventional T cells (Yang et al., 2011). Not surprisingly 
CD62L remained low on MAIT cells at all three phases: homeostatic uninfected MAIT cells, 
activated MAIT cells (during infection) and antigen experienced MAIT cells (>day30 p.i.) (Fig. 3d). 
This observation is consistent with their cytokine responsiveness and the notion that MAIT cells gain 
their effector/memory phenotype during thymic development. 
 
Accumulated lung MAIT cells following infection are enriched for CD8+ cells 
Previous analyses of MAIT cells in mice suggest that they can include CD4+, CD8+ and DN cells 
(Martin et al., 2009; Reantragoon et al., 2013; Tilloy et al., 1999; Treiner et al., 2003), though the 
roles of CD4 and CD8 on MAIT cells have not been determined. The possibility of functional 
differences in these subsets remains intriguing (Treiner et al., 2003; Walker et al., 2012); therefore 
we examined the co-receptor expression on responding MAIT cells in lungs of mice infected with S. 
Typhimurium (Fig. 4). MAIT cells recovered from the lungs of mice pre-infection were mainly DN 
(>95%) with some CD8+ (~5%), and only a small proportion (<1%) expressing CD4 (Fig 4 and not 
shown). In contrast, lung T cells from S. Typhimurium-infected mice showed a preferential 
expansion of CD8+ MAIT cells (including both CD8ab and CD8aa (not shown) (CD8+ MAIT cell 
count pre-infection ~5.3x103; p.i. 3.7 x106, a ~700-fold increase) to comprise up to 20% of MAIT 
cells over the period to d21 p.i. (Fig. 4b-c). While this enrichment for CD8+ MAIT cells could imply 
functional specialisation, or a lower threshold for activation for these compared to other MAIT cells, 
the cytokine profiles of the different MAIT cell subsets from infected lungs was comparable (not 
shown).  
 
MAIT cells proliferate in the lungs of infected mice 
In order to determine whether MAIT cell accumulation in the lungs following intranasal infection 
was a result of their local proliferation, or recruitment from the blood or other sites, we used 5-
bromo-2´-deoxyuridine (BrdU) incorporation over a 2 h window to create a snapshot of proliferation 
at different tissue sites. C57BL/6 mice were infected intranasally with S. Typhimurium BRD509 then 
followed for 7 weeks (Fig. 5a). The enrichment of MAIT cells as a proportion of all ab-T cells was 
most evident in the lungs of infected mice (at d7, 35% of ab-T cells and up to 50% in some 
experiments) but was only evident in the draining LN and spleen at wk 7 (Fig. 5a, b), suggesting 
redistribution to these sites during the resolution phase of the infection (Fig. 5d). To determine 
whether MAIT cells were proliferating early in response to pathogen exposure, BrdU-incorporation 
was also evaluated for up to 5 d p.i. by administration 2 h prior to sacrifice. Cells stained with BrdU 
were considered to have proliferated in the site sampled, as trafficking between sites was unlikely to 
occur in this short pulse window. MAIT cell proliferation was not detected above background at d1 
p.i. (not shown). At d2, BrdU incorporation was detected in just under 10% of MAIT cells in the 
lung, but was barely detectable in draining mediastinal LN (Fig. 5c), spleen or thymus (not shown). 
MAIT cells incorporating BrdU were detected at d3 and d5 p.i. in the lung, and in greater proportion 
in the draining LN, suggesting that proliferation can occur both locally and later in lymphoid organs 
(Fig. 5c). Only background proliferation of non-MAIT ab-T cells was observed during this time 
period (not shown).  
 
Together, our data show a rapid response by MAIT cells to bacterial lung infection. This was 
dependent on MR1 presentation of riboflavin biosynthesis-derived ligands such as 5-OP-RU. MAIT 
cell accumulation and proliferation, but not CD69 up-regulation, was dependent on a second signal, 
which could be furnished through a TLR2/6 agonist or by bacteria lacking the riboflavin synthesis 
pathway. MAIT cell phenotype and cytokine production were consistent with an effector/memory 
functionality and responsiveness. Thus, MAIT cells appear to bridge innate and adaptive immunity in 
the timing and activation requirements of their response to bacterial infection. 
 
DISCUSSION 
Here we have used MR1 tetramers and S. Typhimurium as a model pathogen in mice to evaluate the 
importance of the riboflavin synthesis pathway in driving MAIT cell responses in vivo, as well as to 
define the phenotypic and functional characteristics of MAIT cells responding to an in vivo bacterial 
infection. The generation of highly specific MR1-tetramers (Corbett et al., 2014; Reantragoon et al., 
2013) has allowed the definition of MAIT cells with greater clarity and precision than has been 
previously possible, thus overcoming the potential confusion engendered by using surrogate markers 
of MAIT cells or transgenic mice. MAIT cells are much less abundant in wild-type mice than humans 
(Tilloy et al., 1999) and there are no antibodies against the mouse Va19 TCR chain, thereby 
necessitating the use of highly specific tools for their detection. Using MR1-Ag tetramers, we first 
show that MAIT cells are readily detectable, albeit in low numbers, in normal mice being most 
abundant in the reproductive tract, lung and liver. In initial experiments on infected mice (not shown), 
we observed that lung infection with Streptococcus pneumonia and Lactococcus lactis did not induce 
significant accumulation of MAIT cells in vivo. We considered that this might reflect the 
physiological production or accessibility of antigen in vivo, or alternatively, the possession of a co-
stimulatory capacity by these organisms necessary to activate MAIT cells. Therefore, we exploited 
the capacity of S. Typhimurium to potently activate MAIT cells in vitro. S. Typhimurium is a 
gastrointestinal pathogen of humans and a systemic pathogen of mice. Systemic clearance of S. 
Typhimurium in mice is dependent on CD4+ T cells, and to a lesser extent CD8+ T cells (Kupz et al., 
2014), but was independent of the presence of MAIT cells, suggesting their redundancy as protective 
T cells in this model. Nevertheless, intranasal infection of mice with S. Typhimurium led to a 
substantial increase in the number of MR1- tetramer+ MAIT cells in the lung, accounting for up to 
50% or more of all pulmonary ab-T cells 7 d p.i. (a ~200 fold enrichment of absolute numbers of 
MAIT versus non-MAIT T cells) (Fig. 1E). This enrichment peaked at d7 and was MR1-dependent, 
as shown genetically (in MR1-/- mice) and by using anti-MR1 mAb treatment to inhibit MAIT cell 
accumulation in the lungs, consistent with previous in vitro activation with S. Typhimurium (Corbett 
et al., 2014; Kjer-Nielsen et al., 2012). The accumulation of MAIT cells was directly related to the 
size of the bacterial inoculum and was characterised by a selective enrichment of CD8+ MAIT cells, 
such that they accounted for >20% of all MAIT cells in the lung 7 days after infection. Of note, a 
study of pulmonary infection of mice with the live vaccine strain of Francisella tularensis defined 
MAIT cells as DN and enriched for Vα19-Jα33 invariant α-chain transcripts by RT-PCR (Meierovics 
et al., 2013), thus not addressing a potential role for CD8+ or CD4+ MAIT cells in response to 
infection. The accumulation of lung MAIT cells in mice infected with S. Typhimurium involved an 
initial expansion of MAIT cells, both in the lungs and then draining lymph nodes, as evidenced by 
BrdU uptake by dividing cells. Interestingly, expanded MAIT cells were long-lived in the lung and 
other tissues, persisting in higher numbers than found in the uninfected mice long after the effective 
elimination of S. Typhimurium, which was cleared to undetectable levels at ~10 weeks. 
 
S. Typhimurium is readily amenable to manipulation of the genes involved in the riboflavin synthesis 
pathway (Rib genes), allowing us to demonstrate that responsiveness of MAIT cells in vivo required 
an intact riboflavin pathway. Hence, MAIT cell accumulation during infection in vivo was abolished 
upon disruption of the key RibD gene responsible for generating the precursor 5-A-RU, which 
generates the dominant MAIT cell ligand, 5-OP-RU. Notably, the double RibD, RibH mutant S. 
Typhimurium strain BRD509DribDH could still induce weak, transient up-regulation of MAIT cell 
CD69 in vitro, but did not induce accumulation or enrichment of MAIT cells in vivo. It remains 
unclear whether there are natural ligands deriving from pathways other than riboflavin synthesis that 
activate MAIT cells in other microbes. The variability of MAIT TCRs from the originally described 
semi-invariant MAIT VaVb combinations (Eckle et al., 2014; Lepore et al., 2014; Reantragoon et al., 
2013) suggests that these receptors may be selected by alternate ligands. This is supported by the 
apparent capacity of MAIT cells to discriminate between pathogen-derived ligands in a clonotype-
dependent manner (Gold et al., 2014). On the other hand, the semi-invariant Va and restricted Vb 
chain usage, the importance of the conserved Tyr 95a residue across the TRAJ33, TRAJ20 and 
TRAJ12 gene segments tested to date and the stereotypic mode of binding of the MAIT TCR to all 
known ligands and analogues studied (Birkinshaw, 2014; Corbett et al., 2014; Eckle et al., 2014; 
Kjer-Nielsen et al., 2012; Patel et al., 2013), suggest a very limited ligand family is recognized by 
MAIT cells. Accordingly, the abrogation of MAIT cell accumulation and their activation following 
mutagenesis of the riboflavin synthesis pathway implies that this pathway furnishes the dominant, 
and likely exclusive, family of natural ligands recognized by MAIT cells at least for S. Typhimurium. 
Previous studies have shown that mature MAIT cells can be directly activated via non-TCR signals 
such as IL-12 and IL-18 (Kurioka et al., 2015; Ussher et al., 2014), and the control of F. tularensis 
intracellular growth required the IL-12 40kDa subunit, implying a need for additional signals from 
infected antigen presenting cells (Meierovics et al., 2013). These observations are consistent with our 
finding that a co-stimulus was required to induce the accumulation of MAIT cells in the lung 
following intranasal administration of synthetic MAIT cell antigen, 5-OP-RU. Intranasal 
administration of purified 5-OP-RU could induce activation of MAIT cells in vivo, as reflected in up-
regulation of CD69 on these cells. However, even repeated intranasal administration of 5-OP-RU 
over a 7 day period did not induce accumulation of lung MAIT cells, suggesting that antigen alone 
was insufficient to induce the full program of MAIT cell responsiveness and accumulation in vivo. In 
contrast, a single intranasal challenge with 5-OP-RU, accompanied by the TLR 2/6 agonist Pam2Cys, 
induced enrichment of lung MAIT cells to the approximate level achieved by infection with S. 
Typhimurium BRD509. Importantly, addition of 5-OP-RU during intranasal challenge with bacteria 
lacking the riboflavin synthesis pathway (BRD509DribDH mutant) also restored their capacity to 
induce MAIT cell accumulation in the lungs, indicating that co-stimulatory capacity is inherent in 
bacterial infection and plays a role in the expansion and responsiveness of MAIT cells following 
infection. Both S. pneumoniae and L lactis possess intact riboflavin synthesis pathways suggesting 
that their inability to induce significant MAIT cell accumulation in the lungs of infected mice could 
reflect inadequate co-stimulatory function. 
 
The phenotype of MAIT cells that expand in response to infection with S. Typhimurium is consistent 
with previous studies of in vitro stimulated MAIT cells, in that they express activation markers even 
before infection, express homing markers for lung rather than lymphoid tissues and produce pro-
inflammatory cytokines IL-17, IFNg and TNF upon activation by microbes. This phenotype is 
consistent with MAIT cell activation in vitro and published studies of the in vivo response to selected 
pathogens such as F. tularensis (Meierovics et al., 2013). However, we also observe a relative 
enrichment of CD8+ MAIT cells in the lungs of mice infected with S. Typhimurium achieved through 
early proliferation of MAIT cells, initially in the lung followed by expansion at other lymphoid sites. 
This expansion may be a consequence of the lower number of MAIT cells in mice versus humans. 
Interestingly, once expanded, the MAIT cells are long lived in primary tissues, preserving their 
activation and homing phenotype, maintaining expression of their transcriptional signature PLZF and 
RORgt but with gradual transition of more MAIT cells to express the transcription factor T-bet, 
known to coordinate developmental and effector programs some of which are conserved across 
adaptive and innate T cells.  
 
Our study presents a picture of MAIT cell responsiveness to pathogens that bridges many of the 
attributes of innate and adaptive immunity, but that is dependent on specific antigen expressed by the 
infecting pathogen. It will be fascinating to unravel whether these cells have evolved in response to a 
range of pathogens with shared antigen(s), or whether they have a more focused role, perhaps 
involving a single pathogen family possibly at a single key site. 
  
FIGURE LEGENDS 
Figure 1. MAIT cells respond to Salmonella in vivo. A) Representative plots showing MAIT cell 
percentage among TCRβ+ lymphocytes in a range of organs from uninfected C57BL/6 mice. MAIT 
cells are defined by MR1-tetramer and TCRβ staining. Numbers represent MAIT cells as a 
percentage of TCRβ+ lymphocytes. B) Representative plots of uninfected C57BL/6 or infected (d7 
p.i.) C57BL/6 or C57BL/6 MR1-/- mice with 106 S. Typhimurium BRD509. C) Treatment of mice 
with anti-MR1 mAb 26.5, but not an isotype control, blocked the accumulation of MAIT cells upon S. 
Typhimurium infection. Three mice per group were injected with 0.25 mg indicated antibodies or no 
Ab i.p. 1 day prior to infection and three times p.i. (d1, d3 and d5). 106 BRD509 were inoculated i.n. 
at day 0. At d7 p.i. mice were killed and lung cells were examined for MAIT cell accumulation. 
Statistics were performed using Student’s t test (**: p<0.01, error bars: SEM). Uninfected MR1-/- 
mice were used as the negative control. The experiment was performed twice with similar results. D) 
Dose (of S. Typhimurium BRD509) response of MAIT cells as a percentage of TCRb+ cells at d7 p.i. 
Five mice per group were examined (Mean +/- SEM). The experiment was performed three times 
with similar results. E) Absolute numbers of MAIT cells (circle), conventional non-MAIT cells 
(triangle) and total TCRb+ cells (square) recovered from lungs were expressed over a time course 
following intranasal infection with 106 S. Typhimurium BRD509. Five mice per group were 
examined (Mean +/- SEM). Absolute number expt done once so far and is being repeated 
 
Figure 2. MAIT cells response depends on both specific riboflavin synthesis-derived antigen and co-
stimulation. A) In vitro activation of Jurkat.MAIT cells by S. Typhimurium rib gene deletion mutant 
strains. S. Typhimurium vaccine strain BRD509 (previously described (45)) was used to generate a 
riboflavin deficient mutant (BRD509DribDH) lacking a gene segment containing ribD and ribH, 
which encode key steps in the pathway. RibD and RibH expression was re-constituted by expression 
on a plasmid (BRD509DribDH+RibDH). Jurkat.MAIT cells were incubated for 6 h with filtered 
culture supernatant from BRD509 or BRD509DribDH mutant (DribDH) or reconstituted mutant 
BRD509DribDH+RibDH in the presence of C1R.MR1 cells. Activation was detected by staining 
with anti-CD69. Data shows mean MFI of gated Jurkat.MAIT cells with SEM as error bars. The 
experiment was performed more than three times with similar results. B) and C) In vivo stimulation 
of MAIT cells by BRD509 and BRD509DribDH S. Typhimurium. B) Representative plots, and C) 
MAIT cells as a percentage of ab-T cells, from the lungs of mice immunised with BRD509 (106) or 
BRD509DribDH (107) Salmonella (i.n.), in combination with 5-OP-RU or 6-FP (200 µl of 1.52 µM 
i.v.) three times at d1, d3 and d5 p.i. Day 7 p.i. data are shown. Three mice per group were examined 
(error bar=SD). The experiment was performed twice with similar results. D) MAIT cells as a 
percentage of ab-T cells in the lungs of mice immunised i.n. with S. Typhimurium BRD509 (106), or 
combinations of Pam2Cys (20 nmol, i.n) and/or 5-OP-RU or 6-FP (50 µl of 1.52 µM i.n.). 5-OP-RU 
or 6-FP was administered twice i.n. 1 and 3 days after Pam2Cys administration). Day 7 post 
inoculation data shown. Three mice per group were examined. Statistics were performed using 
Student’s t test (***: p<0.0001, error bar=SEM). One S. Typhimurium BRD509 immunized mouse 
was used as a positive control. The experiment was performed twice with similar results. E) Mice 
were administered i.n with combinations of Pam2Cys (20 nmol/5 µl per mouse) and/or MAIT cell 
ligands (5-OP-RU, 6-FP, 45 µl of 1.52 µM or 45 µl of PBS, per mouse). For blocking 0.25 mg anti-
MR1 mAb (8F2) was injected i.p. 1 day prior. After 2 h mice were killed and lung cells were 
examined for expression of CD69 as a marker of T cell activation. Data represents MFI of CD69 
expression on MAIT and non-MAIT T cells (pooled cells from 2 mice per group). The experiments 
were carried out independently at 4 different time points (1 and 2 h; 4 and 6 h and 14 h post 
inoculation) not shown. F) Mice were inoculated repeatedly i.n. with indicated MR1 ligands and/or 
co-stimulator. Percentages of MAIT cells of ab T-cells (Mean, or mean +/- SEM) are shown, from 2 
mice: uninfected as negative control; 2 mice each as positive/negative controls: Pam2cys (day0) plus 
4 times of 5-OPRU/6FP (day0, 1, 2 and 3); 3 mice each: 6 times of 5-OPRU/6FP alone (day 0, 1, 2, 3, 
4 and 5). 
 
Figure 3. Cytokine profiling and phenotyping of MAIT cells upon infection with S. Typhimurium 
BRD509. A) Intracellular cytokine staining of MAIT and non-MAIT ab-T cells at d7 p.i. detected 
directly ex vivo, or following stimulation with PMA and ionomycin. The numbers represent the 
percentages of cytokine producing cells from MAIT (upper quadrant) and non-MAIT ab-T cells 
(lower quadrant). B) Expression of transcription factors on MAIT cells in uninfected or infected mice 
at indicated time points. Numbers in the bottom panels represent the percentage of T-bet+ among 
MAIT cells (top quadrant) and conventional non-MAIT cells (lower quadrant). Right hand panel 
shows co-staining of cells with RORgt and T-bet (same data set as left hand panel). The experiment 
was performed three times with similar results. C) Cytokine profile as in B), but showing RORgt and 
T-bet expression. D) MAIT cells maintain an effector memory phenotype following infection. 
Analysis of phenotypic marker expression on MAIT cells isolated from the lungs of mice infected i.n. 
with 106 S. Typhimurium BRD509 at indicated time points. Numbers represent the percentage of 
CD25+ among MAIT cells (top quadrant) or conventional T cells (lower quadrant). Representative 
plots are shown. The experiment was performed XX times with similar results.
 Figure 4. Preferential expansion of CD8+ MAIT cells upon infection with S. Typhimurium BRD509. 
Uninfected or infected mice (106 S. Typhimurium BRD509 i.n.) were killed for examination of 
MAIT cells. A) Gating strategy for CD4 and CD8 staining of cells isolated from the lungs of mice. 
CD8+ MAIT cells are expressed as a percentage of total MAIT cells in the lungs from uninfected or 
infected mice from B) day 7 p.i., and C) over the time of infection course. Data represent Mean +/- 
SEM from 5 mice per group. The experiment was performed XX times with similar results. 
 
Figure 5. MAIT cells proliferate locally in the lung and in the draining LN in response to intranasal 
infection. A) Kinetics of MAIT cell accumulation in lung, mediastinal draining LN and spleen. 
C57BL/6 or C57BL/6.MR1-/- mice were inoculated with BRD509 i.n. Lungs, mediastinal LNs and 
spleens were taken to examine the percentage of MAIT cells among ab-T cells at indicated times p.i. 
The experiment was performed three times with similar results. Data represent Mean +/- SEM from 
five mice per group. Data from C57BL/6.MR1-/- mice are not shown. B) MAIT cell percentage in 
various organs 7 weeks after i.n. S. Typhimurium BRD509 inoculation. Organs from five uninfected 
or infected (day 49 p.i. with 106 BRD509 i.n.) mice were examined for the presence of MAIT cells. 
Retention of MAIT cells from infected mice (black bar) in comparison with uninfected mice (open 
bar) was expressed as percentages of total ab-T cells. The experiment was performed three times 
with similar results C) BrdU incorporation by MAIT cells at early time points. Mice were infected i.n. 
with 106 S. Typhimurium BRD509 or left without infection. At indicated time points, 1 mg BrdU in 
200 µl H2O was injected i.p. 2 h after BrdU injection, mice were killed and organs taken to examine 
BrdU incorporation in MAIT cells and non-MAIT ab-T cells (not shown). The experiments were 
carried out independently at indicated time points (day 2, 3 and 5 p.i.). Data represent mean from two 
mice per group. The experiment was performed twice with similar results. D) Bacterial load. Mice 
were inoculated i.n. with 106 S. Typhimurium BRD509. At indicated time points lungs were 
harvested and homogenised to measure bacterial load by colony count assay. Data represent mean +/- 
SEM The experiment was performed 3 times with similar results. 
 
MATERIALS AND METHODS 
Activation of Jurkat.MAIT cells 
Jurkat cells transduced with genes encoding a MAIT TCR comprising the TRAV1-2-TRAJ33 
invariant a chain, and a TRBV6-1 b chain, were tested for activation by co-incubation with bacterial 
culture supernatant and C1R antigen presenting cells expressing MR1 (CIR.MR1) for 16 h. Cells 
were subsequently stained with PE-conjugated anti-CD3 and APC-conjugated anti-CD69 antibodies 
before analysis by flow cytometry. Activation of Jurkat.MAIT cells was measured by an increase in 
surface CD69 expression.  
 
Compounds and immunogens 
5-OP-RU was prepared as described previously (Corbett et al., 2014). 6-FP was purchased from 
Schirks Laboratories. TLR2/6 agonist Pam2Cys (Tan et al., 2012) was chemically synthesized and 
functionally verified. 
 
Bacterial strains and mutants  
Salmonella enterica serovar Typhimurium BRD509 has been previously described (Hoiseth and 
Stocker, 1981; Newland et al., 1992). BRD509 is an attenuated strain with deletions in aroA and 
aroD, which result in limitation of replication and spread of bacteria (Hoiseth and Stocker, 1981; 
Strugnell et al., 1992) with an intact riboflavin synthesis pathway. The S. Typhimurium 
BRD509ΔribDH mutant was constructed from BRD509 by lamda red-recombinase mediated allelic 
replacement followed by general transduction using phage P22 as previously described (Strugnell et 
al., 1992). S. Typhimurium ΔribDH is unable to make its own riboflavin and its growth needs 
supplementation of riboflavin (20 µg/ml) in the medium.  
Primers: 
B2(Sec)F:  5’-TAG GGA TAA CAG GGT AAT-GGT TCG ATA GCG TAA TGG  
B2(Sec)R:  5’-TAG GGA TAA CAG GGT AAT-TAT CTT TCC GGC CTG TGA  
B2(Kan)F:  5’-CTA AGG AGG ATA TTC ATA TG-GAC CGC GCT TGA AAT GAT  
B2(Kan)R:  5’-GAA GCA GCT CCA GCC TAC ACA-ATT GTT AAC AAT GAC ACA  
 
The complement of mutant BRD509ΔribDH was performed by transformation of ribDH genes 
resulting in strain BRD509ΔribDH+ribDH. Mutation and reconstitution were verified by lack of 
growth or growth on Luria Agar, and by PCR. Mutants were grown on Luria agar containing 20 
µg/ml riboflavin. To prepare supernatant, bacteria were cultured at 37 °C statically, in LB with 
appropriate antibiotics for 16-18 h to log-phase (OD600 0.6-0.9). Supernatant was collected by 
centrifugation, filtered (0.22 µM) and stored at -80oC until use in cellular assays. The number of 
replicating bacteria was estimated from the OD600 and confirmed by plating the inoculums on Luria 
agar containing appropriate antibiotics. 
 
For preparing the infecting inoculum, S. Typhimurium BRD509 or BRD509ΔribDH were grown 
statically in Luria Bertani broth (LB) at 37 °C overnight. BRD509 or BRD509ΔribDH were re-
inoculated in pre-warmed fresh medium for a further 2-4 h static culture to reach OD600 of 0.4-0.6. 
With the estimation that 1 O.D. equals 5 x 108/ml bacteria, sufficient bacteria were washed and 
diluted in PBS for intranasal delivery to mice. A sample of inoculum was plated onto Luria agar with 
appropriate antibiotics for verification of bacterial concentration by counting CFU.  
 
Mice and inoculations 
All C57BL/6 mice and MR1-/- mice (backcrossed to C57BL/6, >10 times) were bred and housed in 
the Biological Research Facility of the Department of Microbiology and Immunology, Peter Doherty 
Institute for Infection and Immunity, University of Melbourne. MR1-/- mice were derived from 
Vα19i.Cα-/-.MR1-/- mice (Kawachi et al., 2006) obtained from Susan Gilfillan (Washington 
University in St. Louis School of Medicine, St. Louis, MO). MR1-/-, mice were generated by 
breeding Vα19i.Cα-/-.MR1-/- mice with C57BL/6 mice, and inter-crossing of F1 mice. The genotype 
was determined by tail DNA PCR at the MR1 locus and by analyzing blood for the presence of intact 
ab-T cells using antibodies against TCRb. The phenotype (absence of MAIT cells) of the MR1-/- 
mouse line was verified by examining MAIT cells in the retired founder breeder mice. Male mice 
aged between 6-12 weeks were used in experiments. All procedures on mice were approved by the 
University of Melbourne Animal Ethics Committee. 
 
Intranasal inoculation with S. Typhimurium (BRD509: 106 or BRD509DribDH: 107 unless otherwise 
stated) or antigens (1.52 µM 5-OP-RU or 6-FP in 50 µl alone, or in 45 µl plus 5 µl of 20 nmol 
Pam2Cys) prepared in 50 µl volume per nares was performed on anesthetized mice. For blocking 
experiments, mice were given 250 µg anti-MR1 (26.5 or 8F2) (Huang et al., 2005, and Chua et al JI 
2013, ) or isotype control mAbs, prepared in house in 200 µl PBS, once (i.v or i.p): once prior to 
inoculation and twice at day 1 and day 4 post inoculation. At different time points post inoculation, 
mice were killed by administration of CO2 and organs: lung (following perfusion with 10 ml cold 
RPMI into the right ventricle of the heart), liver (following perfusion with 10 ml PBS through the 
portal vein), mediastinal lymph nodes, blood, spleen, thymus, vagina and uterus were taken for 
preparation of single cell suspensions. 
 
Preparation of organs and isolation of cells 
Single cell suspensions of lungs, uterus and vagina (pooled form 3 mice) were prepared by firstly 
chopping organs into fine pieces with a scalpel blade. Half the material was resuspended in 0.5 mL 
collagenase III buffer (RPMI with 3 mg/ml collagenase III (Worthington), 1 mg/ml DNAse and 2% 
FCS) and digested for 90 min at 37 °C with gentle shaking. Cells were then filtered (70 µM) and 
washed with PBS/2% FCS. Liver lymphocytes were prepared by pushing liver through a metal mesh, 
Percoll (33.75%) density gradient centrifugation at 693 g, 12 mins, at RT. Single cell suspension 
from lymph nodes, spleen and thymus were prepared by directly pushing the tissues through 70 µM 
cell strainers. RBCs were lysed from lung, liver and spleen preparations with hypotonic buffer TAC 
(Tris-based Amino Chloride, 2.5 ml/half lung) for 5 min at R.T. The OD600 used for a rough 
estimation of cell concentration. Approximately 1.5×106 cells were filtered (40 µm) and used for 
flow cytometric analysis. Blood cells were prepared by centrifugation and serum removal. RBC lysis 
was performed with 1 ml Lysing buffer (BD Biosciences) per sample after staining with 
antibody/tetramer mix for 30 min in the dark.  
 
Determination of bacterial counts in infected lungs.  
Numbers of CFU in organs from infected mice were determined using groups of five or more mice. 
Bacterial colonisation was determined by counting CFU obtained from plating homogenized organs 
from infected mice on Luria agar containing appropriate antibiotics.  
 
Generation of soluble MR1 tetramers  
Murine MR1 and β2-Microglobulin genes were expressed in E. coli inclusion bodies, refolded and 
purified as described previously (Patel et al., 2013). MR1-5-OP-RU and MR1-6-FP tetramers were 
generated as described previously (Corbett et al., 2014) and prepared simultaneously. 
 
Antibodies and flow cytometry 
Antibodies against CD19 (1D3, PerCP-Cy 5.5), CD3 (UCHT1, PE or 145-2C11, PE-Cy7) CD4 
(GK1.5, APC-Cy7), CD45.2 (104, FITC), CD69 (FN50, APC) CD8α (53-6.7, PE), IFNg (XMG1.2, 
PE-Cy7), TCRβ (H57-597, APC or FITC), TNF (MP6-XT22, PE) and IL-17A (TC11-18H10, 
AlexaFluor700) were purchased from BD. Antibodies against MHC II (M5, AlexaFluor700), PLZF 
(Mags.21F7, PE), RORgt (B2D, APC) and T-bet (4B10, PE-Cy7) were purchased from eBioscience. 
Blocking antibodies (26.5 and 8F2) and isotype controls (3E12 and 8A5) were prepared in house. 
 
To block non-specific staining, cells were incubated with MR1-6FP tetramer (1:100) and anti-Fc 
receptor (2.4G2) for 15 min at RT prior to antibody staining. Cells were then incubated at RT with 
antibody cocktails including MR1-5-OP-RU tetramer in PBS/2% FCS. Cells were then further 
incubated with 7-AAD (5 µL/sample) for 10 min in the dark at RT and fixed with 1% PFA prior to 
analysis on an LSRII (BD Bioscience) or LSR Fortessa (BD Bioscience). Analysis of data was 
performed with Flowjo software.  
 
For intracellular cytokine staining, Golgi plug (BD Biosciences) was used during all processing steps. 
Cells stimulated with PMA/Ionomycin (final concentrations 20 ng/ml, 1 µg/ml) were included as 
positive control. Stimulation occurred for 3 h at 37° in 5% CO2 with Golgi plug added. For ICS 
experiments, tetramer surface staining was performed at 37oC. Cells were then stained for 
intracellular cytokines using the BD Fixation/Permeabilisation kit following the manufacturer’s 
instructions. Transcription factor staining was performed using a commercial transcription buffer 
staining set (eBioscience) according to the manufacturer’s instructions. 
 
In vivo BrdU incorporation assay 
B6 mice were inoculated intranasally with 106 S. Typhimurium BRD509 bacteria. At different time 
points, 1 mg BrdU in 100 µl H2O was injected intraperitoneally. After 2 h mice were killed and 
organs taken for assaying BrdU incorporation by following the procedures provided by the 
manufacturer (BrdU Flow Kits, BD Pharmingen). 
 
Statistical analysis  
All statistical tests were performed using Prism software (version 6, GraphPad software, La Jolla, CA, 
USA). Comparisons between groups were performed using Student’s t test, unless otherwise stated.  
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